MedTrace Logo

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

NCT02215616 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2020-05-04

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).

Conditions

Interventions

DRUG

Laquinimod

Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.

DRUG

Placebo

Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-28
Primary Completion
2018-06-19
Completion
2018-06-19
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Czechia
  • Germany
  • Italy
  • Netherlands
  • Portugal
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02215616 on ClinicalTrials.gov